|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
DILTIAZEM INHIBIT CYP-450 ENZYME THUS REDUCING THE CLEARANCE OF THE DRUG, HENCE DOSE OF THE DRUG SHOULD BE REDUCED
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED SERUM LEVELS OF CARBAMAZEPINE RESULTING IN TOXICITY IN SOME PATIENTS
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION HAS RESULTED IN INHIBITION OF HEPATIC CYTOCHROME P450 BY CIMETIDINE PRODUCING SIGNIFICANT INCREASE IN PEAK DILTIAZEM PLASMA LEVELS AND AUC ; AN ADJUSTMENT IN DILTIAZEM DOSAGE MAY BE WARRENTED
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CALCIUM CHANNEL BLOCKERS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS MAY POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY & AUTOMATICITY AS WELL AS VASCULAR DILATATION ASSOCIATED WITH ANAESTHETICS
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS CALCIUM CHANNEL BLOCKER , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CALCIUM CHANNEL BLOCKERS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
DILTIAZEM INHIBIT CYP-450 ENZYME THUS REDUCING THE CLEARANCE OF THE DRUG, HENCE DOSE OF THE DRUG SHOULD BE REDUCED
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
POTENTIATION OF ANTIHYPERTENSIVE DRUGS
|